HOME >> BIOLOGY >> NEWS
Does natural selection drive the evolution of cancer?

(PHILADELPHIA) -- The dynamics of evolution are fully in play within the environment of a tumor, just as they are in forests and meadows, oceans and streams. This is the view of researchers in an emerging cross-disciplinary field that brings the thinking of ecologists and evolutionary biologists to bear on cancer biology.

Insights from their work may have profound implications for understanding why current cancer therapies often fail and how radically new therapies might be devised.

A review by researchers at The Wistar Institute of current research in this new field, published online November 16, will appear in the December issue of the journal Nature Reviews Cancer.

"A tumor cell population is constantly evolving through natural selection," says Carlo C. Maley, Ph.D., an assistant professor in the Molecular and Cellular Oncogenesis Program at Wistar whose own research focuses on this area. He is senior author on the new review. "The mutations that benefit the survival and reproduction of cells in a tumor are the things that drive it towards malignancy.

"Evolution is also driving therapeutic resistance," Maley adds. "When you apply chemotherapy to a population of tumor cells, you're quite likely to have a resistant mutant somewhere in that population of billions or even trillions of cells. This is the central problem in oncology. The reason we haven't been able to cure cancer is that we're selecting for resistant tumor cells. When we spray a field with pesticide, we select for resistant pests. It's the same idea."

Maley notes that there are three necessary and sufficient conditions for natural selection to occur and that all are met in a population of tumor cells. The first requirement is that there be variation in the population. This variation is evident in tumors, which are a mosaic of many different genetic mutants.

The second condition is that the variation must be heritable. This, too, can be s
'"/>

Contact: Franklin Hoke
hoke@wistar.org
215-898-3716
The Wistar Institute
17-Nov-2006


Page: 1 2 3

Related biology news :

1. Innovative research technique reveals another natural wonder in Yellowstone Park
2. Researchers witness natural selection at work in dramatic comeback of male butterflies
3. Sundried tide -- silent, natural disaster
4. Eavesdropping comes naturally to young song sparrows
5. Academy paleontologist and Alaska artist in line for natural history awards
6. Slow but sure -- Burned forest lands regenerate naturally
7. Life-long learning -- nature provides natural inspiration for education
8. Targeting tumors the natural way
9. New research finds that a natural family planning method is as effective as the contraceptive pill
10. Problem forgetting may be a natural mechanism gone awry
11. Hidden-hero microbes in soil, water may help naturally clean toxic sites

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Does natural selection drive the evolution cancer

(Date:11/7/2014)... , Nov. 7, 2014  In conjunction with the ... Police Departments, The Community Foundation of the Verdugos has announced ... DNA JUSTICE PROJECT," a $250,000 initiative to keep the Verdugo ... In its first six months of existence, the Lab has ... support for local law enforcement. "Because our number ...
(Date:11/6/2014)... cancer deaths occur because of metastasis, yet progress ... been slow. , "It,s been particularly challenging to ... Gujral, research fellow in systems biology at Harvard ... detected until after they,ve already metastasized." , Gujral ... that should help researchers better understand how metastasis ...
(Date:11/5/2014)... Santamaria, associate professor of biology in the UTSA ... in the nation selected to receive a two-year ... for Exploratory Research (EAGER). The funding supports President ... researchers to create new technology that will demystify ... complex behaviors in neuroscience are broken into the ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
(Date:11/21/2014)... 20, 2014 Polaris Group announced today ... its Phase 1 trial of ADI-PEG 20 in ... of malignant pleural mesothelioma (MPM) and non-squamous non-small ... trials on ADI-PEG 20, both as monotherapy and ... of several other indications, including breast cancer, melanomas, ...
(Date:11/21/2014)... GUELPH, ON , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... month and nine month periods ended September 30, 2014.  Biorem,s complete ... SEDAR ( www.sedar.com ). Financial Summary:Three-months ended ... CDN$,000 except per share data) , 2014 , ... , 2,282 , 5,281 , 6,715 ...
(Date:11/18/2014)... (PRWEB) November 17, 2014 ... open architecture blade-based and rackmount computing infrastructure, today ... K80 dual-GPU accelerator throughout its GPU-enabled blade server ... of the company’s latest proprietary 80-lane Gen3 PCIe ... discrete NVIDIA Tesla K80 dual-GPU accelerator cards in ...
(Date:11/18/2014)... New Brunswick, NJ (PRWEB) November 18, 2014 ... of Data Quality and Transparency Reporting solutions, announced ... has gone live using its Consummate Provider™ solution ... Consummate Provider™ is a Global, SaaS based, Data ... Science organizations and their third party Providers improve ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
Cached News: